These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6814753)

  • 41. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preparation and in vitro cytotoxicity of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer.
    Umemoto N; Kato Y; Endo N; Takeda Y; Hara T
    Int J Cancer; 1989 Apr; 43(4):677-84. PubMed ID: 2784785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construction of murine phage antibody library and selection of ricin-specific single-chain antibodies.
    Gao X; Huang Y; Zhu S
    IUBMB Life; 1999 Nov; 48(5):513-7. PubMed ID: 10637767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
    Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
    Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Actinomycin D and x-radiation suppression of spontaneous tumorigenesis in mice.
    Mason JM; Jennings BR
    J Reticuloendothel Soc; 1974 Feb; 15(2):96-111. PubMed ID: 4815216
    [No Abstract]   [Full Text] [Related]  

  • 46. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutron capture using boronated monoclonal antibody directed against tumor-associated antigens.
    Barth RF; Johnson CW; Wei WZ; Carey WE; Soloway AH; McGuire J
    Cancer Detect Prev; 1982; 5(3):315-23. PubMed ID: 7151064
    [No Abstract]   [Full Text] [Related]  

  • 48. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.
    Nabekura T; Nagasawa T; Nakauchi H; Onodera M
    Cancer Immunol Immunother; 2008 May; 57(5):611-22. PubMed ID: 17786440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunotoxins].
    Jansen FK; Blythman HE; Carrière D; Casellas P; Dussossoy D; Gros O; Gros P; Laurent JC; Paolucci F; Pau B; Poncelet P; Richer G; Vidal H; Voisin GA
    Bull Cancer; 1983; 70(3):165-8. PubMed ID: 6882931
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
    Robak T
    Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
    [No Abstract]   [Full Text] [Related]  

  • 53. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.
    Germain C; Larbouret C; Cesson V; Donda A; Held W; Mach JP; Pèlegrin A; Robert B
    Clin Cancer Res; 2005 Oct; 11(20):7516-22. PubMed ID: 16243826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relation between the tumor-specific antigen and cytological characteristics in mouse mammary tumors.
    Irie RF; Koyama K; Hino S
    J Natl Cancer Inst; 1970 Sep; 45(3):515-24. PubMed ID: 5523194
    [No Abstract]   [Full Text] [Related]  

  • 55. Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody.
    Umemoto N; Kato Y; Hara T
    Cancer Immunol Immunother; 1989; 28(1):9-16. PubMed ID: 2783302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoclonal antibody targeting of anti-cancer agents.
    Baldwin RW; Byers VS
    Springer Semin Immunopathol; 1986; 9(1):39-50. PubMed ID: 2425442
    [No Abstract]   [Full Text] [Related]  

  • 57. Active specific immunotherapy using the immune reaction of a low-dose irradiated tumor tissue.
    Ogawa Y; Imanaka K; Ashida C; Takashima H; Imajo Y; Kimura S
    Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):533-7. PubMed ID: 6853254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity.
    Miyazaki H; Beppu M; Terao T; Osawa T
    Gan; 1980 Dec; 71(6):766-74. PubMed ID: 6974113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenic enhancement by neuraminidase.
    Oxley S; Griffen WO
    Surg Forum; 1971; 22():113-4. PubMed ID: 5121313
    [No Abstract]   [Full Text] [Related]  

  • 60. Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy.
    Neville DM; Youle RJ
    Immunol Rev; 1982; 62():75-91. PubMed ID: 7042541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.